QIAGEN N.V. (QGEN) recently partnered with Genomics England to support the delivery of the Generation Study. QIAGEN’s Clinical Knowledge Base will power a first-of-its-kind whole-genome sequencing study for 100,000 newborns to screen over 200 selected conditions, enabling earlier diagnosis and treatment of rare conditions.The latest partnership aims to broaden the utilization of QIAGEN’s Genomics portfolio.Likely Trend of QGEN Stock Following the NewsFollowing the announcement, shares of the company remaine ...

QIAGEN’s (QGEN) business is expected to benefit from its expanded test menu of key platforms and strategic collaborations. Yet, the company faces a challenging macro environment. An intense competitive environment and exchange rate fluctuations may dent the results of operations. The stock carries a Zacks Rank #3 (Hold).Factors Driving QGEN StockQIAGEN’s long-term business strategy involves entering into strategic alliances as well as marketing and distribution arrangements with academic, corporate and othe ...

QIAGEN N.V.’s (QGEN) solid potential in the molecular diagnostics area is poised to help it grow in the coming quarters. The company continues to progress with its test menu expansion, building a solid foundation to achieve its long-term targets. Strategic collaborations with Eli Lilly are helping it develop and market its existing and potential products. Meanwhile, the adverse impact of macroeconomic challenges as well as intense competition remain a concern for QIAGEN’s operations.In the past year, this Z ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The Z ...

QIAGEN N.V. (QGEN) has announced plans to move its QIAstat-Dx operations to a new site in Esplugues de Llobregat as part of a multi-year investment to strengthen this business. Slated to open in early 2026, the new site builds on the long-standing presence of the company in the Barcelona area and will cover the entire value chain for the QIAstat-Dx system.The site will include teams such as Research & Development (R&D), Manufacturing, Sales, Marketing, Quality Assurance and Regulatory Affairs. Additionally, ...

QIAGEN N.V. (QGEN) recently launched two new tools for designing and ordering custom solutions to support microbial analysis of bacterial, fungal and viral targets. These new tools should enable researchers to customize their assays and panels for use on the QIAcuity digital PCR (dPCR) system and any third-party next-generation sequencing (NGS) system. These customizable digital PCR assays will be available on QIAGEN’s GeneGlobe web portal. QGEN Stock’s Trend Following the NewsSubsequent to the news, QGEN's ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are ...

QIAGEN's (QGEN) business is expected to get a boost from its growing molecular diagnostic market, expanded test menu and growth-driving strategic collaborations. Yet, the company faces a challenging macro environment. An intense competitive environment and exchange rate fluctuations may dent the results of operations. The stock carries a Zacks Rank #3 (Hold) at present.Factors Driving QGEN StockMolecular testing is the most dynamic segment of the global in vitro diagnostics market. QIAGEN offers one of the ...

Company Performance - Qiagen's total revenue for the quarter ending September 2024 was $501.87 million, a 5.5% year-over-year increase [4] - Asia Pacific, Japan, and Rest of World contributed $75.06 million (14.96% of total revenue), a -2.51% surprise compared to the expected $76.99 million [5] - Europe, Middle East, and Africa contributed $158.18 million (31.52% of total revenue), a -0.58% surprise compared to the expected $159.11 million [6] Revenue Projections - Wall Street analysts project Qiagen's revenue for the ongoing fiscal quarter to be $522.77 million, a 2.7% increase from the year-ago quarter [7] - Asia Pacific, Japan, and Rest of World are expected to contribute 15.6% ($81.38 million) and Europe, Middle East, and Africa 32.8% ($171.69 million) to the total revenue [7] - For the entire year, Qiagen's total revenue is forecasted to be $1.97 billion, a 0.3% improvement from the previous year [8] - Asia Pacific, Japan, and Rest of World are expected to contribute 15.5% ($306.3 million) and Europe, Middle East, and Africa 32.6% ($642.48 million) to the total revenue [8] Stock Performance - Over the past month, Qiagen's stock has declined by 0.4%, while the Zacks S&P 500 composite has increased by 4.4% [13] - The Zacks Medical sector, Qiagen's industry group, has declined by 1.4% over the same period [13] - Over the past three months, Qiagen's stock price has declined by 6.3%, while the S&P 500 index has risen by 13.1% [13] - The broader sector has declined by 2% during this interval [13] Market Context - The global economy's deep interlinkage makes a company's engagement with international markets critical for financial success and growth [2] - International market involvement serves as insurance against domestic economic downturns and enables engagement with faster-growing economies [3] - Qiagen's reliance on foreign markets presents a mix of opportunities and challenges, making vigilant monitoring of international revenue movements essential for projecting the company's future direction [9]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.W ...